Safety Profiles of Enfortumab Vedotin and Erdafitinib in Bladder Cancer Treatment
Author Information
Author(s): Huang Yuanbin, Xu Meiqi, Ma Xinmiao, Wang Wei, Shen Chen, Liu Fei, Chen Zhiqi, Wang Jiawen, Guo Qian, Li Xiancheng
Primary Institution: Second Affiliated Hospital of Dalian Medical University
Hypothesis
This study assessed adverse drug reactions (ADRs) from both drugs, comparing their safety profiles to guide clinical use.
Conclusion
The study identified and compared potential and novel ADRs between EV and Erdafitinib, providing key insights into their safety profiles.
Supporting Evidence
- 3,438 ADR reports were identified, with 2,257 for EV and 1,181 for Erdafitinib.
- EV is linked to higher rates of skin and nervous system disorders compared to Erdafitinib.
- Erdafitinib has a higher mortality rate associated with its ADRs compared to EV.
Takeaway
This study looked at the side effects of two cancer drugs, Enfortumab vedotin and Erdafitinib, to help doctors choose the best treatment for patients.
Methodology
A retrospective descriptive analysis was conducted on ADR reports for EV and Erdafitinib from the WHO-VigiAccess database.
Potential Biases
Reporting biases, including notoriety bias and selective reporting, may affect the interpretation of the data.
Limitations
The study is limited by potential reporting biases and the lack of accurate exposure population information.
Participant Demographics
{"gender_distribution":{"male":73.8,"female":23.3,"unknown":2.9},"age_distribution":{"65-74":25.4,"≥75":20.2,"unknown":37.6},"geographic_distribution":{"Americas":51.1,"Europe":44.6,"Asia":3.1,"Africa":0.1,"Oceania":1.1}}
Statistical Information
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website